These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Waldum HL; Brenna E; Sandvik AK Expert Opin Drug Saf; 2002 May; 1(1):29-38. PubMed ID: 12904157 [TBL] [Abstract][Full Text] [Related]
4. Is there a dark side to long-term proton pump inhibitor therapy? Nealis TB; Howden CW Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138 [TBL] [Abstract][Full Text] [Related]
5. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943 [TBL] [Abstract][Full Text] [Related]
7. Considerations for long-term use of proton-pump inhibitors. Garnett WR Am J Health Syst Pharm; 1998 Nov; 55(21):2268-79. PubMed ID: 9825878 [TBL] [Abstract][Full Text] [Related]
8. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Freston JW Am J Gastroenterol; 1997 Apr; 92(4 Suppl):51S-55S; discussion 55S-57S. PubMed ID: 9127627 [TBL] [Abstract][Full Text] [Related]
9. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Jensen RT Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Huang JQ; Hunt RH Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532 [TBL] [Abstract][Full Text] [Related]
11. Personal review: is profound acid inhibition safe? Waldum HL; Brenna E Aliment Pharmacol Ther; 2000 Jan; 14(1):15-22. PubMed ID: 10632641 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Blume H; Donath F; Warnke A; Schug BS Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963 [TBL] [Abstract][Full Text] [Related]
13. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Robinson M Aliment Pharmacol Ther; 1999 Oct; 13 Suppl 5():5-10. PubMed ID: 10555603 [TBL] [Abstract][Full Text] [Related]
14. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Lamberts R; Brunner G; Solcia E Digestion; 2001; 64(4):205-13. PubMed ID: 11842276 [TBL] [Abstract][Full Text] [Related]
15. Review article: the long-term use of proton-pump inhibitors. Raghunath AS; O'Morain C; McLoughlin RC Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():55-63. PubMed ID: 16042660 [TBL] [Abstract][Full Text] [Related]
16. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?]. Maléth J; Hegyi P Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385 [TBL] [Abstract][Full Text] [Related]
17. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Metz DC Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353 [TBL] [Abstract][Full Text] [Related]
18. Safety data required for proton-pump inhibitor use in children. Scaillon M; Cadranel S J Pediatr Gastroenterol Nutr; 2002 Aug; 35(2):113-8. PubMed ID: 12187284 [No Abstract] [Full Text] [Related]
19. Review article: proton pump inhibitors and bacterial overgrowth. Williams C; McColl KE Aliment Pharmacol Ther; 2006 Jan; 23(1):3-10. PubMed ID: 16393275 [TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]